Merus incurred a $95.5 million net loss in Q3 2025, with revenues rising slightly to $12.2 million. Increased R&D costs, particularly for petosemtamab trials, drove higher operating expenses. Collaboration revenue from Gilead and Incyte partially offset the expenses. Cash reserves increased, bolstering liquidity into 2028.